

Supplement Fig. 1


List of target genes

Select DNA Rearrangement								
ALK	BCL2	BCL6	BCR	BRAF	CCND1	CRLF2	EGFR	EPOR
ETV1	ETV4	ETV5	ETV6	EWSR1	FGFR2	IGH	IGK	IGL
JAK1	JAK2	KMT2A	MYC	NTRK1	PDGFRA	PDGFRB	RAF1	RARA
RET	ROS1	TMPRSS2	TRG					
Select Gene Fusions								
ABI1	ABL1	ABL2	ACSL6	AFF1	AFF4	ALK	ARHGAP26	ARHGEF12
ARID1A	ARNT	ASXL1	ATF1	ATG5	ATIC	BCL10	BCL11A	BCL11B
BCL2	BCL3	BCL6	BCL7A	BCL9	BCOR	BCR	BIRC3	BRAF
BTG1	CAMTA1	CARS	CBFA2T3	CBFB	CBL	CCND1	CCND2	CCND3
CD274	CDK6	CDX2	CHIC2	CHN1	CIC	CIITA	CLP1	CLTC
CLTCL1	CNTRL	COL1A1	CREB3L1	CREB3L2	CREBBP	CRLF2	CSF1	CTNNB1
DDIT3	DDX10	DDX6	DEK	DUSP22	EGFR	EIF4A2	ELF4	ELL
ELN	EML4	EP300	EPOR	EPS15	ERBB2	ERG	ETS1	ETV1
ETV4	ETV5	ETV6	EWSR1	FCGR2B	FCRL4	FEV	FGFR1	FGFR1OP
FGFR2	FGFR3	FLI1	FNBP1	FOXO1	FOXO3	FOXO4	FOXP1	FSTL3
FUS	GAS7	GLI1	GMPS	GPHN	HERPUD1	HEY1	HIP1	HIST1H4I
HLF	HMGAA1	HMGAA2	HOXA11	HOXA13	HOXA3	HOXA9	HOXC11	HOXC13
HOXD11	HOXD13	HSP90AA1	HSP90AB1	IGH	IGK	IGL	IKZF1	IL21R
IL3	IRF4	ITK	JAK1	JAK2	JAK3	JAZF1	KAT6A	KDSR
KIF5B	KMT2A	LASP1	LCP1	LMO1	LMO2	LPP	LYL1	MAF
MAFB	MALT1	MDS2	MECOM	MKL1	MLF1	MLLT1	MLLT10	MLLT3
MLLT4	MLLT6	MN1	MNX1	MSI2	MSN	MUC1	MYB	MYC
MYH11	MYH9	NACA	NBEAP1	NCOA2	NDRG1	NF1	NF2	NFKB2
NIN	NOTCH1	NPM1	NR4A3	NSD1	NTRK1	NTRK2	NTRK3	NUMA1
NUP214	NUP98	NUTM2A	OMD	P2RY8	PAFAH1B2	PAX3	PAX5	PAX7
PBX1	PCM1	PCSK7	PDCD1LG2	PDE4DIP	PDGFB	PDGFRA	PDGFRB	PER1
PHF1	PICALM	PIM1	PLAG1	PML	POU2AF1	PPP1CB	PRDM1	PRDM16
PRRX1	PSIP1	PTCH1	PTK7	RABEP1	RAF1	RALGDS	RAP1GDS1	RARA
RBM15	RET	RHOH	RNF213	ROS1	RPL22	RPN1	RUNX1	RUNX1T1
RUNX2	SEC31A	SEPT5	SEPT6	SEPT9	SET	SH3GL1	SLC1A2	SNX29
SRSF3	SS18	SSX1	SSX2	SSX4	STAT6	STL	SYK	TAF15
TAL1	TAL2	TBL1XR1	TCF3	TCL1A	TEC	TET1	TFE3	TFG
TFPT	TFRC	TLX1	TLX3	TMPRSS2	TNFRSF11A TOP1	TP63	TPM3	
TPM4	TRIM24	TRIP11	TTL	TYK2	USP6	WHSC1	WHSC1L1	YPEL5
ZBTB16	ZMYM2	ZNF384	ZNF521					

•NA Gene List

Supplement Fig. 2

Median, interquartile range, and outlier for time from assay request to clinical report.



Supplement Fig. 3 Concordance rate of fusion transcript detection by G-banding karyotyping and NGS


		NGS		Cohen's κ
G-banding karyotyping	CBF fusion transcript	Detected	16	2
		Not Detected	1	146
	KMT2A- rearrangement	Detected	8	1
		Not Detected	2	154
	Total	Detected	24	3
		Not Detected	3	135

The fusion genes used in the evaluation are as follows,

CBF fusion transcript, t(8;21)(q22;q22.1);RUNX1-RUNXT1, inv(16)(p13.1;q22) or t(16;16)(p13.1;q22);CBFB-MYH11

KMT2A-rearrangement, t(9;11)(p21.3;q23.3);KMT2A-MLLT3, t(11;19)(q23;q13.1);KMT2A-MLLT1, t(10;11)(p12;q23);KMT2A-MLLT10, t(1;11)(q21;q23);KMT2A-MLLT11, t(6;11)(q27;q23);KMT2A-MLLT4, t(X;11)(q13;q23);KMT2A-SEPT6 t(11;17)(11;17);KMT2A-SEPT9


Supplement Fig. 4

Fusion partner of *KMT2A* rearrangement and *NUP98* rearrangement

Red arrows indicate the site of translocation.


Supplement Fig. 5

Survival curves classified by single-hit or multi-hit groups of TP53 mutations.




Supplement Fig. 6

Survival curves classified by age at enrollment.

Overall Survival

Supplement Fig. 7 Schematic overview of mutation sites of *WT1* in the analysis cohort.



Supplement Fig. 8

Distribution of *WT1* expression values with or without *WT1* mutation.